超52亿美元！彭博：Genmab (CSE: GMAB)计划收购Merus（NASDAQ:MRUS）获EGFR/LRG5双抗

Core Viewpoint - Genmab A/S is in advanced negotiations to acquire Merus NV, a Dutch biotechnology company focused on innovative cancer therapies, which could be announced in the coming days [1][26]. Group 1: Company Overview - Genmab, headquartered in Copenhagen, has a market capitalization of approximately $18.6 billion, while Merus has a market capitalization of about $5.2 billion [4][12]. - If completed, this acquisition would mark Genmab's largest transaction in its history, emphasizing its commitment to strengthening its oncology pipeline [12]. Group 2: Merus and Its Innovations - Merus has attracted interest from several large pharmaceutical companies due to its experimental cancer drug, petosemtamab, which has shown promising clinical trial data in significantly reducing tumors in head and neck cancer patients [9][10]. - The combination of petosemtamab with Merck's Keytruda has demonstrated better efficacy than existing standard therapies, enhancing investor confidence and boosting Merus's stock price [9][10]. Group 3: Strategic Implications - The acquisition of Merus could provide Genmab with a strategic advantage in the competitive immuno-oncology market, expanding its drug portfolio and increasing collaboration opportunities with pharmaceutical giants [12]. - This move reflects a broader trend in the biotechnology sector, where established companies actively seek mergers and acquisitions to acquire breakthrough technologies and promising drug candidates [12].